FDA Panel Gives Nod To Spondyloarthritis Claim For Cimzia, But Not Humira
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee narrowly endorses approval of UCB’s TNF inhibitor but recommends the proposed indication for active disease be more limited. The same panel overwhelmingly rejects AbbVie’s bid to expand adalimumab’s use on concerns that the patient population studied was not well defined.
You may also be interested in...
Humira Shows Benefit In New Arthritis Indications Based On Novel Criteria
Abbott’s anti-TNF demonstrated an improvement in two subsets of spondyloarthritis patients using new criteria developed by the SpondyloArthritis International Society to identify and test patients.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.